Momordica charantia polysaccharides modulate the differentiation of neural stem cells via SIRT1/β-catenin axis in cerebral ischemia/reperfusion

Zhaoli Hu†, Fengying Li†, Xiaoling Zhou†, Feng Zhang†, Linyan Huang‡, Bing Gu‡, Jiangang Shen‡ and Suhua Qi†,‡*

Abstract

Background: Stroke is the leading cause of long-term motor disability and cognitive impairment. Recently, neurogenesis has become an attractive strategy for the chronic recovery of stroke. It is important to understand the molecular mechanism that promotes neural stem cell (NSC) neurogenesis for future NSC-based therapies. Our previous study showed that Momordica charantia polysaccharides (MCPs) exerted neuroprotective effects on stroke via their anti-oxidant and anti-inflammation activities. However, it remains unknown whether MCPs promote NSC neurogenesis after cerebral ischemic/reperfusion injury (IRI).

Methods: We investigated MCPs’ function in differentiation of neural stem cells (NSCs) in vivo and in vitro experiments. Based on a middle cerebral artery occlusion (MCAO) rat model, the effect of MCPs on neuronal differentiation after MCAO was analyzed. Primary NSCs and neural stem cell line C17.2 were cultured and subjected to glutamate stimulation to establish the cell model of IRI. We evaluated the effect of MCPs on NSC differentiation in IRI cell model by Western blot and immunofluorescence staining. The SIRT1 activity of NSCs post glutamate stimulation was also evaluated by CELL SIRT1 COLORIMETRY ASSAY KIT. In addition, molecular mechanism was clarified by employing the activator and inhibitor of SIRT1.

Results: MCPs had no effects on the differentiation of neural stem cells under physiological conditions while shifted NSC differentiation potential from the gliogenic to neurogenic lineage under pathological conditions. Activation of SIRT1 with MCPs was responsible for the neuronal differentiation of C17.2-NSCs. The neuronal differentiation effect of MCPs was attributed to upregulation SIRT1-mediated deacetylation of β-catenin. MCP-induced deacetylation via SIRT1 promoted nuclear accumulation of β-catenin in NSCs.

(Continued on next page)
Introduction
Stroke is a major disease that affects millions of people annually across the world [1–3]. As far as we have known that, after the onset of cerebral ischemia, a set of time-dependent cellular events are activated including not only glutamate receptor-mediated excitotoxicity, apoptosis, and blood-brain barrier (BBB) dysfunction and inflammation but also endogenous neural repair [4, 5]. Accumulating evidence has suggested that the neurogenesis occurs in rodents, as well as in primate and patients after ischemic stroke [6–8]. However, the spontaneous repair capacity after cerebral ischemia is limited because proximately 80% of the new neurons produced by ischemia die within 2 weeks, and only a very few populations can survive over a long period of time [9, 10]. Therefore, pharmacological interventions related to promoting endogenous neurogenesis and prolonging the survival of differentiated neurons after stroke are believed to be a promising strategy for brain repair.

Momordica charantia (MC), belonging to the gourd family, is an important multipurpose edible, medicinal plant widely distributed throughout Asia. In recent study, we have provided experimental evidence for that polysaccharide is main effective components extracted from MC. Additionally, Monordicia charantia polysaccharides (MCPs) have a protective role on nerve injury after stroke by scavenging free radicals [11]. The other teams’ previous research also demonstrated that MCPs have high anti-oxidant capacity for scavenging reactive oxygen species (ROS) [12, 13]. The side effects of currently prescribed synthetic anti-oxidants have prompted the use of alternative traditional herbal medicines and dietary supplements anti-oxidants associated with fewer adverse effects in the treatment of ischemia stroke [14]. It is well established that variety of natural molecules present in the diet, such as plant polysaccharide, could protect the brain and delay aging. Emerging studies show a role for anti-oxidant-rich foods such as fruits, vegetables, and nuts in improving cognitive damage by preventing or delaying the onset of cognitive decline during aging and neurodegeneration [15, 16]. As naturally compounds found in daily foods, MCPs are well-known for their anti-oxidation, anti-inflammation, anti-tumor, hypoglycemic, and anti-diabetic effects [17]; however, little is known about its effects from neurogenesis regulation perspective.

Silent information regulator factor 2-related enzyme 1 (sirtuin1, SIRT1) is a deacetylase which is widely expressed in the whole adult brain [18] and has been shown to interact with set of protein targets involved in Wnt signaling [19], glucose homeostasis [20, 21], and calcium signaling [22, 23], making SIRT1 an attractive candidate target for controlling senescence, feeding behavior, energy expenditure, and oxidative stress [24]. By deacetylating a variety of proteins, SIRT1 can mediate a broad range of vital biological functions including gene expression, DNA repair and apoptosis, neurogenesis, and aging. Thus, SIRT1 promotes cellular longevity through a number of mechanisms [25]. Studies of the aging brain have shown that the expression of SIRT1 decline with age, which is accompanied by a higher incidence of aging related diseases in mammals, such as ischemic stroke [26–28]. In addition, SIRT1 has been found to delay aging and considered to be one of the determining factors of the biology of stem cells, including neural stem cells (NSCs) and neural progenitor cells (NPCs). SIRT1 has been implicated in NSCs proliferation and differentiation through deacetylating variety of histone and non-histone proteins and transcription factors [29, 30]. These phenomena raise the possibility that SIRT1 may play a crucial role on neurogenesis after ischemic stroke.

During recent years, canonical Wnt/β-catenin signaling has been found to play a key role in controlling the maintenance of neural stem cells and the development of neural tissues and progenitor cells [31]. The accumulation of β-catenin in the nucleus is the key step in canonical Wnt/β-catenin signaling pathway [32]. Furthermore, the post-translational modification of β-catenin, including phosphorylation and deacetylation, is an important mechanism of regulating of β-catenin stability and subcellular location, as well as its transcriptional activity [33, 34]. However, it has not previously been explored whether MCPs regulate nuclear translocation of β-Catenin via SIRT1 to promote differentiation of NSCs after stroke. Therefore, in the present study, we aim to determine whether MCPs could improve NSC differentiation and to further explore whether SIRT1/β-catenin axis plays roles in post-stroke neurogenesis.

(Continued from previous page)

**Conclusion:** Our findings indicate that the deacetylation of β-catenin by SIRT1 represents a critical mechanism of action of MCPs in promoting NSC neuronal differentiation. It provides an improved understanding of molecular mechanism underlying neuroprotective effects of MCPs in IRI, indicating its potential role on treating ischemic stroke especially chronic recovery.

**Keywords:** Momordica charantia polysaccharides (MCPs), Neural stem cells (NSCs), Differentiation, SIRT1, β-Catenin
Material and methods
MCPs preparation
MCPs (purity ≥ 99%) were extracted from *M. charantia* by water extraction and alcohol precipitation, followed by the elimination of proteins and starch. Studies in our team [11] have identified MCPs composition by high performance liquid chromatography (HPLC) and mass spectrometry (MS). HPLC-MS/MS analysis revealed that galacturonic acid was the major ingredients of MCP accounted for 93.7% and rhamnose, xylose, mannose, glucose, and galactose were in the molar ratio of 0.06%, 0.18%, 0.03%, 0.8%, and 0.28%, respectively. The extraction method was provided by Professor Min Wang from China Pharmaceutical University.

Antibody and reagents
The following primary antibodies were used in this study: mouse anti-SIRT1 antibody [19A7AB4] (1 μg/ml, ab110304, Abcam), rabbit anti-β-catenin antibody [E247] (1:5000; ab32572, Abcam), rabbit anti-BrdU antibody (1:1000, B35138, Life technologies), mouse anti-beta III Tubulin antibody [TUJ-1] (1:1000, ab14545, Abcam), mouse anti-MAP 2 antibody (1:1000; ab5392, Abcam), mouse MAb anti-GFAP antibody (1:1000; ab106509, Abcam), mouse anti-CNPase antibody [11-5B] (5 μg/ml, ab6319, Abcam), mouse anti-acetyl Lysine antibody [IC6] (1:1000; ab22550, Abcam), rabbit monoclonal anti-Lamin B1 antibody (1:3000, #13435, Cell Signaling Technology, USA), and β-actin (1:5000, #4970, Cell Signaling Technology, USA). The secondary antibodies used in our experiment were goat anti-mouse IgG (1:10000) and goat anti-rabbit IgG (1:10000), which were purchased from Sigma-Aldrich (St. Louis, MO, USA). SIRT1 small interfering RNA (siRNA) (#5239398) was obtained from Life Technologies (USA). Resveratrol was obtained from Sigma-Aldrich (St. Louis, MO, USA). Nicotinamide was acquired from Beyotime biotechnologies (USA). Normal goat serum stock solution was purchased from ZSGB-BIO (#ZLI-9021, China).

Middle cerebral artery occlusion (MCAO) model
Adult male Sprague-Dawley rats (240~280 g) were obtained from Shanghai Experimental Animal Center of the Chinese Academy of Science. All the surgical procedures were in accordance with the institutional guidelines, and the experimental procedures were approved by the Animal Ethics Committee of Xuzhou Medical University (approval ID, SCXK (SU) 2010-0003). The rats were maintained in standard cages in a controlled environment (temperature, 24 ± 1 °C; relative humidity, 50~60%; light period, 06:00~18:00) and given access to food and water ad libitum. The rats were used in the study after 3 days of acclimatization. The middle cerebral artery occlusion (MCAO) stroke model was performed with 5 h of MCAO plus reperfusion 14 days. Briefly, rats were anesthetized with 4% isoflurane and maintained at 2% isoflurane via inhalation. In MCAO group, a silicon-coated suture with a tip diameter of 0.38 mm (Doccol, Redlands, CA, USA) was inserted from the external carotid artery (ECA) into the internal carotid artery (ICA), until its tip occluded the origin of the left middle cerebral artery (MCA). In the sham group, rats underwent the same anesthesia and surgical procedure without MCA occlusion.

Experimental groups and drug administration
All treatments were administered in a blinded manner. Rats were randomly divided into 3 groups with six mice per group (Fig. 1): (1) sham operation rats, (2) MCAO rats, and (3) MCAO rats treated with MCPs (200 mg/kg) after MCAO. The rats treated with MCPs were subjected to intragastric administration of MCPs (200 mg/kg) every 24 h for 2 weeks after MCAO.

Brain section immunofluorescence labeling
Anesthetized rats were perfused through the left ventricle with ice saline followed by ice 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4). Brains were quickly removed and fixed with the same fixation solution overnight at 4 °C. The tissue was gradient dehydrated with 20% and 30% sucrose for 24~48 h. Twenty-micrometer coronal sections were taken from fresh frozen mouse brains. After washing with 0.01 M PBS, the slices were incubated with blocking buffer (PBS with 10% goat serum and 0.5% Triton X-100) for 2 h at RT. For in situ hybridization, double immunofluorescence was used to co-localize BrdU plus Tuj1 (MAP 2, GFAP, or CNP) in the same slices overnight at 4°C. Then, appropriate fluorescent antibody was added and incubated at room temperature for 1 h followed by staining of the nuclei with DAPI (10 mg/mL). Images were obtained with a digital microscope (Olympus CKX53, Japan) and analyzed by Image-Pro Plus 6.0 software.

Cell culture
C17.2 cells are an immortalized NSC line originally derived from external germinal layer of mouse cerebellum. For the unique ability to self-renew and generate both neurons and glia in vitro, this cell line is predominately used as a model for multipotent stem cells [35]. In the present study, C17.2 cells were kindly provided by Professor Jiangang Shen (School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, SAR, China). C17.2 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) containing 10% fetal bovine serum (FBS, Gibco) and 2 mM L-glutamine at 37 °C in humidified incubators with a 5% CO₂ atmosphere and passaged at 50% confluence every 2 days.
Establishment of ischemia reperfusion cell model and drug treatment

Glutamate is the major excitatory neurotransmitter in the central nervous system. Early events following ischemic damage include reactive oxygen species (ROS)-mediated oxidative stress and glutamate-induced excitotoxicity, both of which contribute to rapid cell death within the infarct core. Exposure to glutamate, implicated in damage induced by oxidative stress, is usually used as an in vitro model of ischemia/reperfusion-induced cell death. For mimic this damage in vitro, the model of injured NSCs by glutamate was built up. The detailed method was described as previously reported [36, 37]. Briefly, for C17.2 cells, glutamate-mediated neurotoxicity was induced by 30 min exposure to 100 \( \mu \text{M} \) glutamate in the normal feeding medium. For restoration, cultured C17.2 cells were rinsed twice with PBS and the original feeding medium was restored for different period of times (0 days, 1 day, 3 days, 4 days, 5 days, 14 days) to establish glutamate-induced insults in vitro.

For drug treatments, MCPs at various concentrations (1.0, 2.0, 3.0, 5.0, 10.0, and 20.0 \( \mu \text{g/ml} \)) were added into cell cultures for 24 h after the end of glutamate exposure. To activate or inhibit Sirt1, C17.2 cells were pre-incubated with resveratrol (Sirt1 activators, 25 \( \mu \text{M} \)) or nicotinamide (Sirt1 inhibitors, 25 \( \mu \text{M} \)) for 24 h prior to glutamate exposure.

Primary cortical neural stem cells (E16-NSC) culture

All procedures involving the use of animals were approved by the local ethical review committee. Primary cortical neural stem cells (E16-NSC) were isolated from cerebral cortices of Sprague-Dawley rat embryo on E16. Briefly, whole cerebral neocortices were removed from the rat fetuses, then mechanically dissociated. The single-cell suspension was transfected to 6-cm culture dishes and cultured as floating neurospheres in a humidified atmosphere with 5% CO\(_2\) at 37 °C. Neurospheres were maintained in neural-basal medium (DMEM/F-12, 1:1, Hyclone), which was supplemented with B27-supplement, 20 \( \mu \text{g/l}\) basic bFGF and 20 ng/ml EGF (both from Invitrogen), 2 mmol/L-glutamine (Invitrogen), and 10,000 U/l penicillin and 10 mg/l streptomycin (both from Hyclone). After 5–7 days, the neurospheres were trypsinised (0.05% trypsin with 0.02% EDTA, Sigma-Aldrich) as single-cell and seeded in poly-D-lysine-treated culture plates at a density of 5 × 10\(^4\) cells. Then, cells were cultured for 2 to 3 days at 37 °C in a 7.5% CO\(_2\) atmosphere and used for in vitro experiment.

siRNA transfection

Small interfering RNAs (siRNAs, 5239398) targeting sir1 were obtained from Life Technologies. Six-well plates were plated with C17.2-NSCs for transfection, and when cells reached 60 to 70% confluence, the lipofectamine 3000
(Invitrogen, Carlsbad, CA, USA) were used to transfected cells with either SIRT1-specific small interfering RNA (siRNA) (50 nM) or negative control siRNA (50 nM) mixed with Lipofectamine RNAiMAX (all from Life Technologies) according to the manufacturer's instructions. All transfected cells were harvested at 48 h after transfection for subsequent experiment.

Cellular immunofluorescence staining
For differentiation detection, the expression of Tuj1, GFAP, and CNP were analyzed by cellular immunofluorescence staining. The cells were seeded on glass coverslips in DMEM supplemented with 10% FBS. Coverslips were rinsed with PBS and then fixed with 4% paraformaldehyde solution for 10 min at room temperature (RT). After fixation, the cells were incubated in blocking buffer (1× PBS with 5% normal goat serum stock solution) for 1 h at RT. Then, cells were rinsed three times with 0.01 M PBS (pH 7.4), incubated with the primary antibody (anti-Tuj1, anti-GFAP, or anti-CNP), overnight at 4°C, washed with PBS for three times, and then incubated with the secondary antibody (Alexa Fluor 488-conjugated goat anti-mouse antibody, 1:200, Invitrogen) for 2 h at RT, and DAPI (10 mg/mL) was added 15 min to display the nuclei. Images of 10 randomly selected fields of view were captured under a fluorescence microscope.

Protein sample and subcellular protein sample preparation
The cells were washed three times with iced PBS and lysed using 300~400 μL lysis buffer (containing 50 mM Tris-HCl, 140 mM NaCl, 1.5 mM MgCl₂, 0.5% NP-40, 1 mM Na₃VO₄, 1 mM p-nitrophenyl phosphate, 0.5 mM PMSF, 10 μg/mL leupeptin, 10 μg/mL aprotinin, and 10 μg/mL pepstatin) on ice for 30 min before collection. The mixture was then centrifuged to isolate the supernatant, which contained the cytoplasmic protein. The pellet was washed by adding 400 μL of lysis buffer and then centrifuged to discard the supernatant. The pellet was re-suspended with 100 μL of RIPA lysis (containing 50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM Na₃VO₄, 1 mM p-nitrophenyl phosphate, 0.5 Mm PMSF, 10 μg/mL leupeptin, 10 μg/mL aprotinin, and 10 μg/mL pepstatin). After three ultrasonic treatments for 5 s at intervals of 5 s and centrifugation at 12,000×g for 20 min at 4°C, the supernatant was the nuclear protein.

Immunoprecipitation
Coimmunoprecipitation (co-IP) was performed according to the following procedures. Briefly, protein samples were precleared for 1 h at 4°C using 20 μL of protein A-Sepharose CL-4B (Amersham Biosciences, Uppsala, Sweden) to remove nonspecific proteins. After centrifugation, supernatants were incubated with 1 μg of primary antibodies overnight at 4°C. Targeted immune complexes were captured with 2 h incubation of protein A. Samples were eluted three times with immunoprecipitation buffer. Targeted proteins were eluted by boiling at 100°C for 5 min in SDS-PAGE loading buffer and then isolated by centrifugation. Then, immunoprecipitates were subjected to Western blot analysis.

Immunoblotting
Western blot analysis was performed according to the standard protocol. Briefly, proteins were separated by 4–12% SDS-PAGE and transferred to PVDF membranes (Merck KGaA, Darmstadt, Germany) for 90 min at 15 V. The membranes were then blocked with 5% non-fat dry milk in Tris-buffered saline and Tween 20 (TBST) and then incubated with appropriate primary antibodies at 4°C overnight, followed by washing with TBST, then incubating with horseradish peroxidase-conjugated secondary antibodies in TBST for 1 h at RT. Then, the bands were visualized by ECL (Pierce) and detected by Bio-Rad digital imaging system (Bio-Rad Laboratories, Inc.). For quantification, the density of the bands on the membrane was quantified using Image J 1.48 software.

Assessment of SIRT1 activity
Sirt1 deacetylase activity was determined with the CELL SIRT1 COLORIMETRY ASSAY KIT (GenMed Sciences Inc., USA) based on FluordeLys-SIRT1 substrate peptide. Protein extracts from C17.2 cells were incubated with the fluorogenic acetylated peptide substrate. The reaction was carried out at 37°C for 1 h, and the fluorescent signal was measured at 360 nm excitation and 460 nm emission on a fluorescence plate reader. Results were expressed as percentage of the control.

Data analysis and statistics
All values are presented as the means ± SD. Statistical analysis of the results was carried out by one-way or two-way ANOVA, followed by Duncan’s new multiple range method or the Newman-Keuls test. P values < 0.05 were considered be statistically significant. All of the experiments were repeated at least three times in an independent manner.

Results
MCPs enhance neuronal differentiation of the subgranular zone (SGZ) after MCAO in rats
To further explore the effect of MCPs on neuronal differentiation in vivo, we performed double-labeling at day 14 after MCAO with antibodies against BrdU (red), a marker for DNA replication in newly formed cells, plus TUJ1 (green), BrdU (red) plus MAP 2 (green), BrdU (red) plus...
GFAP (green), or BrdU (red) plus CNP (green) to detect neurons, astrocytes, or oligodenrocytes, respectively. Analysis of the microphotographs of brain sections obtained at days 14 after surgery showed (Fig. 1a, b) that IR injury led to an increase of co-localization between BrdU (red) plus TUJ1 (green) or BrdU (red) plus MAP 2 (green) in the cellular layer. After 14-day MCP treatment, it is noted that neuronal specific marker co-localization with BrdU exhibited enhancement signal, but another two gliogenic specific marker, GFAP (green) or CNP (green), co-localization with BrdU in SGZ in the MCPs-treated animals did not differ from sham operated (Fig. 1c, d). These results suggested that MCP treatment promoted hippocampal SGZ neuronal differentiation of NSCs in MCAO rats.

**MCPs have no effects on the differentiation of neural stem cells under physiological conditions**

To determine whether MCP treatment affects NSC differentiation under physiological conditions, we observed the expression of three NSC differentiation marker genes, including TUJ1, GFAP, and CNP at 24 h after reperfusion in C17.2-NSCs. MCP treatment affects NSC differentiation under physiological conditions, as displayed in Fig. 2, no significant difference was discovered between the Con group and the different concentrations of MCP treatment groups (1.0, 3.0, 5.0, 10.0, and 20.0 μg/ml) in Tubulin, GFAP, or CNP expression. The data suggest that MCP treatment could not affect NSC differentiation under physiological conditions.

**MCPs shift NSC differentiation potential from the gliogenic to neurogenic lineage under pathological conditions**

To exclude the effect of C17.2-NSCs themselves differentiation on the experiment and to determine the time point of MCP administration, C17.2 cells were treated with 30 min of glutamate (100 μM) and then were subsequently restored for different period of times to mimic ischemic induced in vitro. Firstly, we examine differentiation of C17.2-NSCs without the presence of MCPs by monitoring the protein level of three NSC differentiation markers. The results from Western blot assays indicated that the expression of TUJ1, GFAP, and CNP gradually declined on day 0 and reached its lowest point on day 3 and then started to increase on day 5 after glutamic acid stimulation compared with the control cells (Fig. 3a, b). Upon glutamic acid treatment for 14 days, expression of TUJ1 dramatically decreased again and the other two cell markers GFAP and CNP still maintained higher level (Fig. 3a, b).

Next, as shown in Fig. 3c and d, upon MCP treatment, the expression of TUJ1 was significantly increased in different concentrations MCP treatment groups compared with that in the control group and Glu/3d group. While the expression of GFAP dramatically decreased compared with that in the control group and Glu/3d group, in contrast, no change of the protein level of CNP were found compared with the Glu/3d group (Fig. 3c, d). Taken together, these results suggested that MCPs could obviously promote C17.2-NSC differentiation into neuron under the ischemic pathological state.

To further demonstrate the effect of MCPs on NSC differentiation, primary cortical neural stem cells (E16-NSC) were isolated and identified. Immunofluorescent staining (Supplementary figure S 1.) showed that cultured E16-NSCs cells were mostly stem cells, with almost no neurons, astrocytes, or oligodendrocytes, and exhibited strong proliferative ability. In addition, we also detected the differentiation profile of E16-NSC in response to glutamate-inducing stimuli (Supplementary figure S 2.). The results indicated that glutamate treatment in vitro
could successfully induce the change of phenotype in cultured E16-NSC. Therefore, this cell model was used for subsequent differentiation experiments. We detected three lineage-specific differentiation markers (TuJ1, GFAP, and CNP) by immunofluorescent staining (Fig. 3e). As observed in the earlier experiments shown in Fig. 3c and d, glutamate treatment reduced both TuJ1-, GFAP-, and CNP-positive cells. Upon treatment with MCPs, the number of TuJ1-positive cells was significant increased compared with glutamate treatment group. However, MCP treatment had no significant impact on the number of GFAP- or CNP-positive cells (Fig. 3e). Taken together, these findings indicated that MCPs may enhance the neuronal differentiation of E16-NSCs under oxidative stress induced by glutamate.

**Activation of SIRT1 with MCPs is responsible for the neuronal differentiation of C17.2-NSCs**

For insight into further evaluating neuronal differentiation mechanisms of MCP treatment in C17.2-NSCs post glutamate stimulation, we measured SIRT1 protein expression by Western blot. As shown in Fig. 4a and b, the expression of SIRT1 in Glu group was obviously higher compared to that of Con group. Similarly, in MCP group, it was significantly increased compared with Con group. But MCP administration did not remarkably affect SIRT1 protein expression when compared to that in Glu group. Next, we detected the activity of SIRT1 by SIRT1 activity assay. The result (Fig. 4c) showed that the activity of SIRT1 in both concentration of MCP groups were upregulated compared
with Glu group, indicating that MCP treatment enhanced activity of SIRT1.

In order to further study the role of SIRT1 in MCPs induced neuronal differentiation, the blockage of SIRT1 activity by nicotinamide (SIRT1 inhibitors) were used to investigated NSC differentiation. Western blot result showed that MCPs enhanced TUJ1 expression; in contrast, the nicotinamide (NA) abolished the promotion effect of MCPs on neuronal differentiation (Fig. 4d, e).

Additionally, we used SIRT1-siRNA (represented as MCP + siRNA group) to suppress the expression of SIRT1 in the differentiation process and then detected the immunofluorescence staining of TUJ1 (green) and DAPI (blue) in C17.2-NSCs from indicated group. Scale bar, 100 μm. g Quantitative analysis showing the percentage of TUJ1+ cells in indicated group. Data were given as mean ± SD according to ANOVA with n = 3 independent experiments in triplicate per group. *P < 0.05 vs. Con, **P < 0.05 vs. MCP group.
MCP-induced deacetylation via SIRT1 promotes nuclear accumulation of β-catenin in NSCs

The level of acetylation β-catenin was measured by Western blot analysis in C17.2-NSCs under ischemia-mimic condition. The results revealed that, as the time of reperfusion was prolonged, the level of acetylation β-catenin was significantly increased (Fig. 5a, b). Then, we tested the subcellular distribution of β-catenin in nuclear and cytoplasmic, respectively. The results showed that treatment with MCPs (5 or 10 μM) in C17.2-NSCs strongly resulted in a decrease in cytoplasm presence of β-catenin and an increase nuclear accumulation of β-catenin (Fig. 5c–e). Collectively, the above results implied that MCPs could affect distribution of β-catenin, and it may be closely related to the level of β-catenin acetylation via SIRT1. To confirm whether SIRT1 could regulate nuclear accumulation of β-catenin, resveratrol, an agonist of SIRT1, was used as the positive control for the evaluation of the effect of MCPs. As demonstrated in Fig. 5f and g, resveratrol significantly reduced the acetylation level of β-catenin and promoted its nuclear migration under the glutamate insults in C17.2-NSCs, while the nicotinamide, SIRT1 deacetylase inhibitor, increased the acetylation level of β-catenin and inhibited intracellular migration of β-catenin. To further validate whether the MCPs could play the same effect, we detected the acetylation levels of β-catenin in the presence of MCPs or SIRT1 siRNA and observed that MCPs remarkably downregulated the acetylation level of β-catenin and promoted its nuclear accumulation which

![Image](Image_url)
were reversed by the SIRT1 siRNA (Fig. 5h, i). These results confirmed that effect of MCPs was mediated by the SIRT1/β-catenin axis.

**Discussion**

In this study, our results revealed that MCPs could promote NSC neurogenesis after ischemic stroke. Our in vivo and vitro results identified previously unrecognized mechanisms that MCPs led to the activation of SIRT1 under glutamate-induced injury, which positively enhanced the nuclear accumulation of β-catenin and contributed to NSC differentiation into neuron in mimic IRI cell model. These findings indicate that MCPs may have the potential as a protective agent on late-stage recovery of ischemic stroke in clinical practice.

Recent years, polysaccharides have been widely used in medicine because of their low toxicity and obvious pharmacological effects [16]. As natural compounds found in daily foods, water extract of MCPs is well known for its antioxidation, anti-inflammation, anti-tumor, hypoglycemic, and anti-diabetic functions [13]. Several reports have shown that MCP treatment ameliorates oxidative stress injury in cardiovascular and cerebrovascular disease [38]. We have previously investigated that MCPs had a protective role on nerve injury after stroke by scavenging free radicals [11]. However, the mechanism underlying MCP-mediated neuroprotection in stroke and its pro-differentiation effect on injured brain tissues is still far from being understood. This is the first investigation detailing the neuronal differentiation action of MCPs in IRI.

Firstly, we observed that MCP can promote the differentiation of neural stem cells into neurons in SGZ region of MCAO model. We subsequently conducted in vitro study to explore the molecular mechanism of these important findings. To gain insight into the molecular mechanisms of the differentiation effect of MCPs on endogenous NSCs, an immortalized murine-derived neural stem cell line, C17.2-NSCs, was treated with different concentration of MCPs and then were detected the expression of NSC differentiation marker genes. We observed MCPs had no effects on the differentiation of neural stem cells under physiological conditions. This result suggests that MCPs (at different concentration ranges, 1.0, 3.0, 5.0, 10.0, 20.0 μg/ml) is safe for normal physiological NSCs and indicates that such concentration ranges may be physiologically acceptable for cultured cells in vitro. Next, in order to exclude the effect of C17.2 cells themselves differentiation on the experiment and to determine the time point of MCP administration, C17.2-NSCs were treated with glutamate and then were restored for different periods of time to mimic IRI. According to this experiment, we found that the differentiation features of C17.2-NSCs in IRI are consistent with previous reports. In glutamate-induced injury experiment, we aimed to determine the time points when there were the most robust damage effects (Fig. 3a, b). Therefore, we selected 3 days after glutamate treatment to evaluate intervention effects of MCPs. When MCPs was administered to C17.2-NSCs after glutamate-incubation, we observed that MCPs (2.0, 5.0, 10.0 μM) could obviously promote C17.2-NSC differentiation into neuron, in contrast, the astroglial differentiation of C17.2-NSCs were significantly inhibited. However, it seems that MCP concentration does not influence results. These data indicates that the range of effective MCP concentration is wide and has no concentration-dependent effects in our experiment system, and that these concentrations of MCPs do not reach the threshold is yet another possibility.

Astrocytes are the most abundant cells in the CNS and reactive astrogliosis accompany many pathological situations that affect the CNS, such as ischemic damage [39]. Compared with nonreactive astrocytes, reactive astrocytes show either deleterious effects on the progression of tissue damage or beneficial roles during recovery and repair. During recovery stage after IR, overactivated astrocytes can induce multiple damage effects and inhibit survival of newborn neurons [40]. The results of this study appear to suggest that the protective roles of MCPs are to enhance the neuronal differentiation of NSCs on one hand, and another possibility may be that MCPs could change astroglial differentiation which is more important in the recovery stage of CNS injuries. This effect of MCPs on inhibiting the over-activation of glial cells could potentially improve the microenvironment of NSCs survival or could promote neurite outgrowth and synaptic formation during brain repair stage. We have also investigated another primary neural stem cell derived from rat brain, E16-NSCs, and found that MCPs obviously enhance the neuronal differentiation, which strongly supported the results observed from immortalized C17.2-NSCs.

In latest years, therapeutic ability of NSCs has been matter of intense research, fueled by the hope of exploiting their regenerative potential for the treatment of different kinds of neurological impairments [41, 42]. Adult neurogenesis is the process whereby NSCs mature, migrate, and functionally integrate into the pre-existing neuronal network of an adult brain. Thus, the regenerative potential of endogenous neural stem cells in the adult brain has been proved as a likely source for regenerative tool to compensate for neuronal damage after ischemia stroke [43]. However, the molecular mechanisms underlying the regulation of neurogenesis in ischemic stroke remain to be elucidated. Our previous reports have demonstrated that MCPs mitigated ischemic stroke-induced damages by effectively eliminating oxygen free radicals and inhibiting JNK3 activation [11]. Our team has conducted research on the regulation of MCPs on neurogenesis after cerebral
ischemia, and we will elaborate the proliferation effect of MCP on NSCs in another article. Our object of the present study is to focus on effect of MCPs on neuronal differentiation of NSCs under ischemia reperfusion injury and to understand its underlying mechanism.

In addition, to date, seven SIRTs in mammals (SIRT1–SIRT7) have been identified in different subcellular organelles and mediate different cellular functions depending on their typical substrate [24, 44, 45]. Interestingly, due to important effects on metabolism and physiological activities in CNS, SIRT1 has attracted great attention as medicinal targets particularly on neurodegenerative diseases [46]. Mountains of works have confirmed that SIRT1 regulates a wide variety of biological functions and cellular processes through the deacetylation of several histone/ non-histone protein residues [47]. More importantly, cross talk between the gene regulation pathways of multiple transcription factors and SIRT1 determines the expansion and differentiation of stem cells [48]. In general, SIRT1 has drawn more attention because it is deemed to be one of the determining factors of the biology of stem cells. Although increasing evidence has demonstrate that SIRT1 plays a prominent role in the survival of differentiated neurons under various cellular stresses, some other studies have shown different findings. A review article of Cai et al. analyzed the opposing effects of SIRT1 on NSC lineage choice. They suggested a possible explanation that SIRT1 can be neuroprotective or neurotoxic depending on conditions, cellular stress, and cellular type. Another study also demonstrated that upregulation of SIRT1 repressed the proliferation of NPCs and directed their differentiation toward the astroglial lineage at the expense of neuronal lineage under oxidative stress conditions in vitro and in vivo [49]. The conclusion emphasized the importance that SIRT1 function in NSC differentiation depends heavily on the redox state of the cells [24].

With respect to that, MCPs display free-radical scavenging properties; of course, it is entirely possible that MCPs change the redox state of the cells ultimately enhancing the activity of SIRT1. Therefore, in order to test whether the differentiation effect of MCPs was due to SIRT1 in more detail, we showed that MCP administration did not remarkably affect SIRT1 protein expression. But our further studies demonstrated that the activity of SIRT1 in MCP treatment group was upregulated compared with glutamate treatment group, indicating that MCP treatment enhanced activity of SIRT1 during the differentiation process. We also observed that when administering with MCPs, NSC differentiation was promoted into neuron. In contrast, subjecting to NA (a known SIRT1 inhibitor) or knocking down SIRT1 with SIRT1 siRNA, NSC neuronal differentiation was significant downregulated. These results suggested that SIRT1 activation may contribute to the neuronal differentiation effects of MCPs under the ischemic-linked pathological conditions. One possible explanation for this finding is that the strong anti-oxidation of MCPs might change the intracellular redox state of NSCs after glutamate-induced injury, and SIRT1 might be more prone to play its deacetylase activity. This may explain our observation of MCPs promoting neuronal differentiation of NSCs in pathological models, accompanied by an increase in SIRT1 activity.

In our study as discussed above, SIRT1 is critical to MCP-induced NSC differentiation; however, what function might SIRT1 exert there? It is important to note that β-catenin is a deacetylation substrate of SIRT1, and acetylation/deacetylation modification of β-catenin participates in regulating its protein stability and transcriptional activity [50]. Recently, Leonard Guarente’s study showed that SIRT1 could deacetylates β-catenin and promotes its nuclear localization and activity in mesenchymal progenitor cells [51]. Intriguingly, numerous deacetylation substrates of SIRT1 have been identified, for example, one of them is β-catenin, the important transcription factor in Wnt signaling pathway [52, 53]. It is well documented that the protein stability and nuclear localization of β-catenin are required for Wnt pathway target genes, and usually some of those genes are closely related to neurogenesis. Several studies have validated that deacetylation of β-catenin by SIRT1 is correlated with β-catenin nuclear accumulation for its transcriptional activity [33, 50]. For example, a recent study done by Simic group reported that SIRT1-mediated deacetylation was required for nuclear accumulation of β-catenin in mesenchymal stem cells (MSCs) for their self-renewal and differentiation [51]. Therefore, we hypothesize that SIRT1/β-catenin axis participates in NSC differentiation via regulating Wnt signaling pathway in IRI. Therefore, in the final part of study, we observed a significant increased acetylation of β-catenin in glutamate-induced injury of the C17.2-NSCs. More importantly, cell fractionation studies showed that MCP treatment in C17.2-NSCs strongly resulted in a decrease in cytoplasm presence of β-catenin and an increase nuclear accumulation of β-catenin. Further experiments were carried out to verify whether the regulatory effect of MCP on the cellular localization of β-catenin was related to SIRT1. We found that, along with hyperacetylated, β-catenin was decreased in nucleus upon SIRT1 inhibition after stimulation with glutamate. In contrast, incubating with MCPs or RSV (SIRT1 agonist) rescued the nuclear localization defect and reversed the hyperacetylation of β-catenin in C17.2-NSCs. This part of data strongly suggests that MCPs could induce nuclear accumulation of β-catenin via SIRT1 in C17.2-NSCs. And this effect of MCPs is probably related to deacetylase activity of SIRT1. Although the detailed mechanisms underlying
this interesting phenomenon remain to be defined, one plausible explanation is that MCPs are distinct SIRT1 activators which suggest an important potential therapy for ischemic/reperfusion injury.

However, some limitations of our study should be noted. Whether the effect of MCPs on neuronal differentiation is a direct or indirect effect is unknown. In general, due to the large molecular mass and complex composition of polysaccharides, it is difficult to permeate across the blood-brain barrier. Although impaired blood-brain barrier (BBB) under ischemic conditions facilitates MCPs permeate across BBB, affecting the neuronal activities directly, the composition of MCP is complex and diverse which makes it difficult to trace MCPs systematically. To us, this will be an interesting subject for a future study.

**Conclusion**

In conclusion, our study demonstrates that MCPs have the potential to upregulate the activity of SIRT1 by changing intracellular redox state and subsequently motivate the deacetylation of β-catenin, thereby leading to the nuclear accumulation of β-catenin, consequently promoting the neuronal differentiation of NSCs in mimic IRI (Fig. 6). Thus, MCPs may have the potential as a novel neural protective agent in clinical practice. Our study reveals a previously unknown effect of MCPs to promote neuronal differentiation via activating SIRT1/β-catenin pathway in IRI. This finding suggests that, in addition to its commonly known functions of anti-oxidation, MCPs also exhibit anti-inflammation, anti-tumor, and regulate neurogenesis effects. Our study suggests that water extract of MCPs as a potential therapeutic strategy in the treatment of ischemic stroke.

**Supplementary Information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13287-020-02009-2.

**Additional file 1.**

**Abbreviations**

NSCs: Neural stem cells; IRI: Ischemia/reperfusion injury; MCPs: Momordica charantia polysaccharides; siRNA: Small interfering RNA; BBB: Blood-brain barrier; ROS: Reactive oxygen species; SIRT1: Silent information regulator 1; NPCs: Neural progenitor cells

**Acknowledgements**

The authors are grateful to Professor Jiangang Shen for the help in providing C17.2-NSCs.

**Authors’ contributions**

Zhaoli Hu, Fengying Li, Xiaoling Zhou, and Feng Zhang contributed equally to this work. Suhua Qi and Zhaoli Hu designed this study. Zhaoli Hu, Fengying Li, Xiaoling Zhou, and Feng Zhang performed the experiments and collected and analyzed the data. Linyan Huang, Bing Gu, and Jiangang Shen were responsible for the conception and design, assembly of data, and data analyses and interpretation. Zhaoli Hu wrote the manuscript. Suhua Qi and Linyan Huang provided support for the analysis and critical revision of the manuscript. Suhua Qi provided the funds. All authors have read and approved the final manuscript.

**Funding**

This work was supported by Grants of the National Natural Science Foundation of China (No. 81671164), Natural Science Foundation of the Jiangsu Higher Education Institutions of China (No. 13KJA310005), and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institution (No. 2015103130142).

**Availability of data and materials**

The datasets that support our conclusions of the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

All the surgical procedures were in accordance with the institutional guidelines, and the experimental procedures were approved by the Animal Ethics Committee of Xuzhou Medical University (approval ID, SOKK (SU) 2010-0003).
Consen for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Research Center for Biochemistry and Molecular Biology and Jiangsu Key Laboratory of Brain Disease Bioinformation, Xuzhou Medical University, Xuzhou, China. 2School of Medical Technology, Xuzhou Medical University, Xuzhou, China. 3Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. 4School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.

Received: 28 May 2020 Accepted: 26 October 2020 Published online: 16 November 2020

References
1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245–54.
2. Bakker EW, Platt SR, Lau WW, Grace HE, Holmes SP, Wang L, et al. Induced pluripotent stem cell-derived neural stem cell therapy enhances recovery in an ischemic stroke pig model. Sci Rep. 2017;7:10075.
3. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e65–e528.
4. Woodruff TM, Thundil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener. 2011;6:11.
5. Bai SH, Fane M, Park JH, et al. Pin1 promotes neuronal death in stroke by stabilizing notch intracellular domain. Ann Neurol. 2015;77:504–16.
6. Chapouton P, Bally-Cuif L. Neurogenesis. Methods Cell Biol. 2004;76:163–206.
7. Vessal M, Darian-Smith C. Adult neurogenesis occurs in primate sensorimotor cortex following cervical dorsal rhizotomy. J Neurosci. 2010;30(25):8613–23.
8. Boese AC, Le QE, Pham D, Hamblin MH, Lee JP. Neural stem cell therapy for subacute and chronic ischemic stroke. Stem Cell Res Ther. 2018;9(1):154–70.
9. Arvidsson A, Collin T, Kink D, et al. Neural replacement from endogenous precursors in the adult brain after stroke. Nat Med. 2002;8(9):963–70.
10. Calzolari F, Michel J, Baumgart EV, et al. Fast clonal expansion and limited survival of parvalbumin-positive interneurons following cerebral ischemia. eLife. 2015;4:e07197.
11. Gong J, Sun F, Li Y, et al. Momordica charantia polysaccharides: A review of the mechanisms. Int J Biol Macromol. 2018;106:35–48.
12. Kubola J, Siriamornpun S. Phenolic contents and antioxidant activities of Momordica charantia in bitter gourd (Momordica charantia L.) leaf, stem and fruit fraction extracts in vitro. Food Chem. 2008;110(4):881–90.
13. Li J, Wang Y, Huang J, et al. Characterization of antioxidant polysaccharides in bitter gourd (Momordica charantia) L. cultivars. J Food Agric Environ. 2010;8(3):117–20.
14. Qin XJ, He W, Hai CX, et al. Protection of multiple antioxidants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy. J Appl Toxicol. 2008;28(3):271–82.
15. Sarubbo F, Moranta D, Pani G. Dietary polyphenols and neurogenesis: molecular interactions and implication for brain ageing and cognition. Neurosci Behav Rev. 2018;90:456.
16. Gao QH, Fu X, Zhang R, Wang Z, Guo M. Neuroprotective effects of plant polysaccharides: A review of the mechanisms. Int J Biol Macromol. 2018;106:749–54.
17. Jia S, Shen M, Zhang F. Recent advances in Momordica charantia: functional components and biological activities. Int J Mol Sci. 2017;18(12):2555–80.
18. Sakamoto J, Miura T, Shimamoto K, Hiroto Y. Predominant expression of Sirt2, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett. 2004;556(1–3):281–6.
19. Bartoli-Leonard F, Wilkinson FL, Langford-Smith AW, et al. The interplay of SIRT1 and Wnt signaling in vascular calcification. Front Cardiovasc Med. 2018;5:183–91.
20. Pardo PS, Boriek AM. SIRT1 regulation in ageing and obesity. Mech Ageing Dev. 2020. doi:https://doi.org/10.1016/j.mad.2020.111249.
21. Chang C, Su H, Zhang D, et al. AMPK-dependent phosphorylation of GAPDH triggers SIRT1 activation and is necessary for autophagy upon glucose starvation. Mol Cell. 2015;60:390–40.
22. Yang X, Sun X, Wu J, et al. Regulation of the SIRT1 signaling pathway in NMDA-induced Excitotoxicity. Toxicol Lett. 2020;322:66–76.
23. Liu X, Wang N, Zhu Y, et al. Inhibition of extracellular calcium influx results in enhanced IL-12 production in LPS-treated murine macrophages by downregulation of the CaMKKβ-AMPK-SIRT1 signaling pathway. Mediat Inflamm. 2016;2016:1–15.
24. Cai Y, Xu L, Xu H, et al. SIRT1 and neural cell fate determination. Mol Neurobiol. 2016;53(3):2815–25.
25. Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464–71.
26. Miao Y, Zhao S, Gao Y, et al. Curcumin pretreatment attenuates inflammation and mitochondrial dysfunction in experimental stroke: the possible role of SIRT1 signaling. Brain Res Bull. 2016;121:9–15.
27. Petegnief V, Planas AM. SIRT1 regulation modulates stroke outcome. Transl Stroke Res. 2013;4(6):663–71.
28. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Cell Cycle. 2015;14(6):843–55.
29. Libert S, Cohen D, Guarente L. Neurogenesis directed by SIRT1. Nat Cell Biol. 2008;10(4):373–4.
30. Lange C, Mix E, Rateitschak K, Röls A. Wnt signal pathways and neural stem cell differentiation. Neurodegener Dis. 2006;3(1–2):76–86.
31. Bengoa-Vergnoryo N, Kypta RM. Canonical and noncanonical Wnt signaling in neural stem/progenitor cells. Cell Mol Life Sci. 2015;72(21):4157–72.
32. Wang SH, Li N, Wei Y, Li QR, Yu ZP. β-Catenin deactylation is essential for WNT-mediated proliferation of breast cancer cells. Mol Cell Rep. 2014;9(3):973–8.
33. Zhu J, Coyne CB, Sarkar SN. βCAMP alpha regulates Sendai virus-mediated interferon induction through HDAC6 and β-catenin. EMBO J. 2011;30(23):4838–49.
34. Rogers SK, Shapiro LA, Tobin RP, Tow B, Zuzek A, Mukherjee S, Newell-Rogers MK. Levetiracetam differentially alters CD95 expression of neuronal cells and the mitochondrial membrane potential of immune and neuronal cells in vitro. Front Neurol. 2014;5:185.
35. Jiang Q, Gu Z, Zhang G. Nuclear translocation of extracellular signal-regulated kinases in neuronal excitotoxicity. Neuroreport. 2001;12(11):2417–21.
36. Lu C, Chen JQ, Zhou GP, Wu SH, Guan YF, Yuan CS. Multimolecular complex of Par-4 and β1 integrin binding to Smac promoter contributes to glutamate-induced apoptosis in human-bone mesenchymal stem cells. Nucleic Acids Res. 2008;36(15):5021–32.
37. Raish M. Momordica charantia polysaccharides ameliorate oxidative stress, hyperlipidemia, inflammation, and apoptosis during myocardial infarction by inhibiting the NF-κB signaling pathway. Int J Biol Macromol. 2017;97:544–51.
38. Pelény M, Pelinka M. Astrocyte reactivity and reactive astrogliosis and its benefits. Physiol Rev. 2014;94(4):1077–98.
39. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7–36.
40. Ottoboni L, von Wunster B, Martino G. Therapeutic plasticity of neural stem cells. Front Neurol. 2020; Published 2020 Mar 20.
41. Bobkova NV. Poltavetsva RA, Leonov SV. Neuroregeneration regulation in neurodegenerative diseases and aging. Biochemistry (Moscow). 2020;95(5):510–30.
42. Huang, L. Progress in neurobiology. 2018. https://doi.org/10.1016/j.pneurobio.2018.05.004.
43. Frie RA. Phylogenetic classification of prokaryotic and eukaryotic S12-like proteins. Biochem Biophys Res Commun. 2000;272(3):793–8.
44. Blander G, Guarente L. The SIR2 family of protein deacetylases. Annu Rev Biochem. 2004;73(1):417–35.
45. Meng X, Tian J, Li M, Song S, Miao Y, Zhang Q. SIRT1: role under the condition of ischemia/hypoxia. Cell Mol Neurobiol. 2017;37(1):17–28.
46. Rahman S, Islam R. Mammalian SIRT1: insights on its biological functions. Cell Commun Signal. 2011;9(1):1–8.
47. Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J Cereb Blood Flow Metab. 2011;31(4):1003–19.
49. Prozorovski T, Schulze-Topphoff U, Glumm R, et al. SIRT1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol. 2008;10(4):385–94.

50. Chen X, Huan H, Liu C, Luo Y, Shen J, Zhuo Y, Zhang Z, et al. Deacetylation of β-catenin by SIRT1 regulates self-renewal and oncogenesis of liver cancer stem cells. Cancer Lett. 2019; https://doi.org/10.1016/j.canlet.2019.07.021.

51. Simic P, Zainabadi K, Bell E, Sykes DB, Saez B, Lotinun S, et al. SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating β-catenin. Embo Mol Meds. 2013;5(3):430–40.

52. Cohen-Kfir E, Artsi H, Levin A, Abramowitz E, Bajayo A, Gurt I, et al. SIRT1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology. 2011;152(12):4514–24.

53. Iyer S, Han L, Bartell SM, Kim HN, Gubrij I, de Cabo R, et al. Sirtuin1 (SIRT1) promotes cortical bone formation by preventing β-catenin sequestration by FoxO transcription factors in osteoblast progenitors. J Biol Chem. 2014;289(35):24069–78.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.